Antiangiogenic therapy for Kaposi’s sarcoma

Antiangiogenic Cancer Therapy

Volumn , Issue , 2007, Pages 755-784

  Koon, Henry B ^a   Pantanowitz, Liron ^b   Dezube, Bruce J ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

^b TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 36348994234     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1201/9781420004298     Document Type: Chapter

References (202)

1. Campbell, T.B., Borok, M., White, I.E., Gudza, I., Ndemera, B., Taziwa, A., Weinberg, A., and Gwanzura, L., Relationship of Kaposi sarcoma (KS)-associated herpesvirus viremia and KS disease in Zimbabwe, Clin Infect Dis 36 (9), 1144-1151, 2003.
2. Dourmishev, L.A., Dourmishev, A.L., Palmeri, D., Schwartz, R.A., and Lukac, D.M., Molecular genetics of Kaposi’s sarcoma-associated herpesvirus (human herpesvirus-8) epidemiology and pathogenesis, Microbiol Mol Biol Rev 67 (2), 175-212, table of contents, 2003.
3. Hymes, K.B., Cheung, T., Greene, J.B., Prose, N.S., Marcus, A., Ballard, H., William, D.C., and Laubenstein, L.J., Kaposi’s sarcoma in homosexual men-a report of eight cases, Lancet 2 (8247), 598-600, 1981.
4. Ledergerber, B., Telenti, A., and Egger, M., Risk of HIV related Kaposi’s sarcoma and non-Hodgkin’s lymphoma with potent antiretroviral therapy: prospective cohort study. Swiss HIV Cohort Study, BMJ 319 (7201), 23-24, 1999.
5. Von Roenn, J.H., Clinical presentations and standard therapy of AIDS-associated Kaposi’s sarcoma, Hematol Oncol Clin North Am 17 (3), 747-762, 2003.
6. Marcelin, A.G., Roque-Afonso, A.M., Hurtova, M., Dupin, N., Tulliez, M., Sebagh, M., Arkoub, Z.A., Guettier, C., Samuel, D., Calvez, V., and Dussaix, E., Fatal disseminated Kaposi’s sarcoma following human herpesvirus 8 primary infections in liver-transplant recipients, Liver Transpl 10 (2), 295-300, 2004.
7. De Pasquale, R., Nasca, M.R., and Micali, G., Postirradiation primary Kaposi’s sarcoma of the head and neck, J Am Acad Dermatol 40 (2 Pt 2), 312-314, 1999.
8. Pedulla, F., Sisteron, O., Chevallier, P., Piche, T., Saint-Paul, M.C., and Bruneton, J.N., Kaposi’s sarcoma confined to the colorectum: a case report, Clin Imaging 28 (1), 33-35, 2004.
9. Schwartz, R.A., Kaposi’s sarcoma: an update, J Surg Oncol 87 (3), 146-151, 2004.
10. Witte, M.H., Fiala, M., McNeill, G.C., Witte, C.L., Williams, W.H., and Szabo, J., Lymphangioscintigraphy in AIDS-associated Kaposi sarcoma, AJR Am J Roentgenol 155 (2), 311-315, 1990.
11. Ruocco, V., Schwartz, R.A., and Ruocco, E., Lymphedema: an immunologically vulnerable site for development of neoplasms, J Am Acad Dermatol 47 (1), 124-127, 2002.
12. Schwartz, R.A., Cohen, J.B., Watson, R.A., Gascon, P., Ahkami, R.N., Ruszczak, Z., Halpern, J., and Lambert, W.C., Penile Kaposi’s sarcoma preceded by chronic penile lymphoedema, Br J Dermatol 142 (1), 153-156, 2000.
13. Simonart, T., Dobbeleer, G.D., Peny, M., Fayt, I., Parent, D., Vooren, J., and Noel, J., Pre-Kaposi’s sarcoma: an expansion of the spectrum of Kaposi’s sarcoma lesions, Eur J Dermatol 9 (6), 480-482, 1999.
14. Dezube, B.J., Pantanowitz, L., and Aboulafia, D.M., Management of AIDS-related Kaposi sarcoma: advances in target discovery and treatment, AIDS Read 14 (5), 236-238, 243-244, 251-253, 2004.
15. Ioachim, H.L., Adsay, V., Giancotti, F.R., Dorsett, B., and Melamed, J., Kaposi’s sarcoma of internal organs. A multiparameter study of 86 cases, Cancer 75 (6), 1376-1385, 1995.
16. Gill, P.S., Loureiro, C., Bernstein-Singer, M., Rarick, M.U., Sattler, F., and Levine, A.M., Clinical effect of glucocorticoids on Kaposi sarcoma related to the acquired immunodeficiency syndrome (AIDS), Ann Intern Med 110 (11), 937-940, 1989.
17. Trattner, A., Hodak, E., David, M., and Sandbank, M., The appearance of Kaposi sarcoma during corticosteroid therapy, Cancer 72 (5), 1779-1783, 1993.
18. Aboulafia, D.M., Kaposi sarcoma flares during effective antiretroviral treatment, AIDS Read 15 (4), 190-191, 2005.
19. Pantanowitz, L., Dezube, B.J., Pinkus, G.S., and Tahan, S.R., Histological characterization of regression in acquired immunodeficiency syndrome-related Kaposi’s sarcoma, J Cutan Pathol 31 (1), 26-34, 2004.
20. al-Sulaiman, M.H., Mousa, D.H., Dhar, J.M., and al-Khader, A.A., Does regressed posttransplantation Kaposi’s sarcoma recur following reintroduction of immunosuppression? Am J Nephrol 12 (5), 384-386, 1992.
21. Eng, W. and Cockerell, C.J., Histological features of Kaposi sarcoma in a patient receiving highly active antiviral therapy, Am J Dermatopathol 26 (2), 127-132, 2004.
22. Brambilla, L., Boneschi, V., Taglioni, M., and Ferrucci, S., Staging of classic Kaposi’s sarcoma: a useful tool for therapeutic choices, Eur J Dermatol 13 (1), 83-86, 2003.
23. Krown, S.E., Metroka, C., and Wernz, J.C., Kaposi’s sarcoma in the acquired immune deficiency syndrome: a proposal for uniform evaluation, response, and staging criteria. AIDS Clinical Trials Group Oncology Committee, J Clin Oncol 7 (9), 1201-1207, 1989.
24. Nasti, G., Talamini, R., Antinori, A., Martellotta, F., Jacchetti, G., Chiodo, F., Ballardini, G., Stoppini, L., Di Perri, G., Mena, M., Tavio, M., Vaccher, E., D’Arminio Monforte, A., and Tirelli, U., AIDS-related Kaposi’s sarcoma: evaluation of potential new prognostic factors and assessment of the AIDS Clinical Trial Group Staging System in the Haart Era-the Italian Cooperative Group on AIDS and Tumors and the Italian Cohort of Patients Naive from Antiretrovirals, J Clin Oncol 21 (15), 2876-2882, 2003.
25. Cornelissen, M., van der Kuyl, A.C., van den Burg, R., Zorgdrager, F., van Noesel, C.J., and Goudsmit, J., Gene expression profile of AIDS-related Kaposi’s sarcoma, BMCCancer 3 (1), 7, 2003.
26. Facchetti, F., Lucini, L., Gavazzoni, R., and Callea, F., Immunomorphological analysis of the role of blood vessel endothelium in the morphogenesis of cutaneous Kaposi’s sarcoma: a study of 57 cases, Histopathology 12 (6), 581-593, 1988.
27. Francis, N.D., Parkin, J.M., Weber, J., and Boylston, A.W., Kaposi’s sarcoma in acquired immune deficiency syndrome (AIDS), J Clin Pathol 39 (5), 469-474, 1986.
28. Gottlieb, G.J. and Ackerman, A.B., Kaposi’s sarcoma: an extensively disseminated form in young homosexual men, Hum Pathol 13 (10), 882-892, 1982.
29. Dictor, M. and Andersson, C., Lymphaticovenous differentiation in Kaposi’s sarcoma. Cellular phenotypes by stage, Am J Pathol 130 (2), 411-417, 1988.
30. Green, T.L., Meyer, J.R., Daniels, T.E., Greenspan, J.S., de Souza, Y., and Kramer, R.H., Kaposi’s sarcoma in AIDS: basement membrane and endothelial cell markers in late-stage lesions, J Oral Pathol 17 (6), 266-272, 1988.
31. Pantanowitz, L., Tahan, S.R., Pinkus, G.S., and Dezube, B.J., Morphologic and immunophenotypic evidence of in-situ Kaposi’s sarcoma (abstract), Arch Pathol Lab Med 129, 556, 2005.
32. Roth, W.K., Brandstetter, H., and Sturzl, M., Cellular and molecular features of HIV-associated Kaposi’s sarcoma, AIDS 6 (9), 895-913, 1992.
33. Nickoloff, B.J. and Griffiths, C.E., The spindle-shaped cells in cutaneous Kaposi’s sarcoma. Histologic simulators include factor XIIIa dermal dendrocytes, Am J Pathol 135 (5), 793-800, 1989.
34. Kanitakis, J. and Roca-Miralles, M., Factor-XIIIa-expressing dermal dendrocytes in Kaposi’s sarcoma. A comparison between classical and immunosuppression-associated types, Virchows Arch A Pathol Anat Histopathol 420 (3), 227-231, 1992.
35. Chor, P.J. and Santa Cruz, D.J., Kaposi’s sarcoma. A clinicopathologic review and differential diagnosis, J Cutan Pathol 19 (1), 6-20, 1992.
36. Kaaya, E.E., Parravicini, C., Ordonez, C., Gendelman, R., Berti, E., Gallo, R.C., and Biberfeld, P., Heterogeneity of spindle cells in Kaposi’s sarcoma: comparison of cells in lesions and in culture, J Acquir Immune Defic Syndr Hum Retrovirol 10 (3), 295-305, 1995.
37. Regezi, J.A., MacPhail, L.A., Daniels, T.E., DeSouza, Y.G., Greenspan, J.S., and Greenspan, D., Human immunodeficiency virus-associated oral Kaposi’s sarcoma. A heterogeneous cell population dominated by spindle-shaped endothelial cells, Am J Pathol 143 (1), 240-249, 1993.
38. Huang, Y.Q., Friedman-Kien, A.E., Li, J.J., and Nickoloff, B.J., Cultured Kaposi’s sarcoma cell lines express factor XIIIa, CD14, and VCAM-1, but not factor VIII or ELAM-1, Arch Dermatol 129 (10), 1291-1296, 1993.
39. Simonart, T., Degraef, C., Heenen, M., Hermans, P., Van Vooren, J.P., and Noel, J.C., Expression of the fibroblast=macrophage marker 1B10 by spindle cells in Kaposi’s sarcoma lesions and by Kaposi’s sarcoma-derived tumor cells, J Cutan Pathol 29 (2), 72-78, 2002.
40. Pantanowitz, L., Dezube, B.J., and Pinkus, G.S., Dendritic cells in the pathogenesis of Kaposi’s sarcoma (abstract), Blood 102, 281-282a, 2003.
41. Corbeil, J., Evans, L.A., Vasak, E., Cooper, D.A., and Penny, R., Culture and properties of cells derived from Kaposi sarcoma, J Immunol 146 (9), 2972-2976, 1991.
42. Nadimi, H., Saatee, S., Armin, A., and Toto, P.D., Expression of endothelial cell markers PAL-E and EN-4 and Ia-antigens in Kaposi’s sarcoma, J Oral Pathol 17 (8), 416-420, 1988.
43. Nickoloff, B.J., The human progenitor cell antigen (CD34) is localized on endothelial cells, dermal dendritic cells, and perifollicular cells in formalin-fixed normal skin, and on proliferating endothelial cells and stromal spindle-shaped cells in Kaposi’s sarcoma, Arch Dermatol 127 (4), 523-529, 1991.
44. Nickoloff, B.J., PECAM-1 (CD31) is expressed on proliferating endothelial cells, stromal spindleshaped cells, and dermal dendrocytes in Kaposi’s sarcoma, Arch Dermatol 129 (2), 250-251, 1993.
45. Rutgers, J.L., Wieczorek, R., Bonetti, F., Kaplan, K.L., Posnett, D.N., Friedman-Kien, A.E., and Knowles, D.M., 2nd, The expression of endothelial cell surface antigens by AIDS-associatedKaposi’s sarcoma. Evidence for a vascular endothelial cell origin, Am J Pathol 122 (3), 493-499, 1986.
46. Scully, P.A., Steinman, H.K., Kennedy, C., Trueblood, K., Frisman, D.M., and Voland, J.R., AIDS-related Kaposi’s sarcoma displays differential expression of endothelial surface antigens, Am J Pathol 130 (2), 244-251, 1988.
47. Uccini, S., Ruco, L.P., Monardo, F., Stoppacciaro, A., Dejana, E., La Parola, I.L., Cerimele, D., and Baroni, C.D., Co-expression of endothelial cell and macrophage antigens in Kaposi’s sarcoma cells, J Pathol 173 (1), 23-31, 1994.
48. Uccini, S., Sirianni, M.C., Vincenzi, L., Topino, S., Stoppacciaro, A., Lesnoni La Parola, I., Capuano, M., Masini, C., Cerimele, D., Cella, M., Lanzavecchia, A., Allavena, P., Mantovani, A., Baroni, C.D., and Ruco, L.P., Kaposi’s sarcoma cells express the macrophage-associated antigen mannose receptor and develop in peripheral blood cultures of Kaposi’s sarcoma patients, Am J Pathol 150 (3), 929-938, 1997.
49. Cheung, L. and Rockson, S.G., The lymphatic biology of Kaposi’s sarcoma, Lymphat Res Biol 3 (1), 25-35, 2005.
50. Marais, B.J., Pienaar, J., and Gie, R.P., Kaposi sarcoma with upper airway obstruction and bilateral chylothoraces, Pediatr Infect Dis J 22 (10), 926-928, 2003.
51. Sugaya, M., Watanabe, T., Yang, A., Starost, M.F., Kobayashi, H., Atkins, A.M., Borris, D.L., Hanan, E.A., Schimel, D., Bryant, M.A., Roberts, N., Skobe, M., Staskus, K.A., Kaldis, P., and Blauvelt, A., Lymphatic dysfunction in transgenic mice expressing KSHV k-cyclin under the control of the VEGFR-3 promoter, Blood 105 (6), 2356-2363, 2005.
52. Witte, M.H., Stuntz, M., and Witte, C.L., Kaposi’s sarcoma. A lymphologic perspective, Int J Dermatol 28 (9), 561-570, 1989.
53. Dictor, M., Carlen, B., Bendsoe, N., and Flamholc, L., Ultrastructural development of Kaposi’s sarcoma in relation to the dermal microvasculature, Virchows Arch A Pathol Anat Histopathol 419 (1), 35-43, 1991.
54. McNutt, N.S., Fletcher, V., and Conant, M.A., Early lesions of Kaposi’s sarcoma in homosexual men. An ultrastructural comparison with other vascular proliferations in skin, Am J Pathol 111 (1), 62-77, 1983.
55. Beckstead, J.H., Wood, G.S., and Fletcher, V., Evidence for the origin of Kaposi’s sarcoma from lymphatic endothelium, Am J Pathol 119 (2), 294-300, 1985.
56. Dorfman, R.F., Kaposi’s sarcoma. The contribution of enzyme histochemistry to the identification of cell types, Acta Unio Int Contra Cancrum 18, 464-476, 1962.
57. Pantanowitz, L., Tahan, S.R., Dezube, B.J., and Pinkus, G.S., Dendritic, endothelial and lymphatic cell markers in Kaposi’s sarcoma (abstract), Mod Pathol 17, 97A, 2004.
58. Fukunaga, M., Expression of D2-40 in lymphatic endothelium of normal tissues and in vascular tumours, Histopathology 46 (4), 396-402, 2005.
59. Kahn, H.J., Bailey, D., and Marks, A., Monoclonal antibody D2-40, a new marker of lymphatic endothelium, reacts with Kaposi’s sarcoma and a subset of angiosarcomas, Mod Pathol 15 (4), 434-440, 2002.
60. Folpe, A.L., Veikkola, T., Valtola, R., and Weiss, S.W., Vascular endothelial growth factor receptor-3 (VEGFR-3): a marker of vascular tumors with presumed lymphatic differentiation, including Kaposi’s sarcoma, kaposiform and Dabska-type hemangioendotheliomas, and a subset of angiosarcomas, Mod Pathol 13 (2), 180-185, 2000.
61. Jussila, L., Valtola, R., Partanen, T.A., Salven, P., Heikkila, P., Matikainen, M.T., Renkonen, R., Kaipainen, A., Detmar, M., Tschachler, E., Alitalo, R., and Alitalo, K., Lymphatic endothelium and Kaposi’s sarcoma spindle cells detected by antibodies against the vascular endothelial growth factor receptor-3, Cancer Res 58 (8), 1599-1604, 1998.
62. Weninger, W., Partanen, T.A., Breiteneder-Geleff, S., Mayer, C., Kowalski, H., Mildner, M., Pammer, J., Sturzl, M., Kerjaschki, D., Alitalo, K., and Tschachler, E., Expression of vascular endothelial growth factor receptor-3 and podoplanin suggests a lymphatic endothelial cell origin of Kaposi’s sarcoma tumor cells, Lab Invest 79 (2), 243-251, 1999.
63. Skobe, M., Brown, L.F., Tognazzi, K., Ganju, R.K., Dezube, B.J., Alitalo, K., and Detmar, M., Vascular endothelial growth factor-C (VEGF-C) and its receptors KDR and flt-4 are expressed in AIDS-associated Kaposi’s sarcoma, J Invest Dermatol 113 (6), 1047-1053, 1999.
64. Wang, H.W., Trotter, M.W., Lagos, D., Bourboulia, D., Henderson, S., Makinen, T., Elliman, S., Flanagan, A.M., Alitalo, K., and Boshoff, C., Kaposi sarcoma herpesvirus-induced cellular reprogramming contributes to the lymphatic endothelial gene expression in Kaposi sarcoma, Nat Genet 36 (7), 687-693, 2004.
65. Carroll, P.A., Brazeau, E., and Lagunoff, M., Kaposi’s sarcoma-associated herpesvirus infection of blood endothelial cells induces lymphatic differentiation, Virology 328 (1), 7-18, 2004.
66. Hong, Y.K., Foreman, K., Shin, J.W., Hirakawa, S., Curry, C.L., Sage, D.R., Libermann, T., Dezube, B.J., Fingeroth, J.D., and Detmar, M., Lymphatic reprogramming of blood vascular endothelium by Kaposi sarcoma-associated herpesvirus, Nat Genet 36 (7), 683-685, 2004.
67. Xu, H., Edwards, J.R., Espinosa, O., Banerji, S., Jackson, D.G., and Athanasou, N.A., Expression of a lymphatic endothelial cell marker in benign and malignant vascular tumors, Hum Pathol 35 (7), 857-861, 2004.
68. Banerji, S., Ni, J., Wang, S.X., Clasper, S., Su, J., Tammi, R., Jones, M., and Jackson, D.G., LYVE-1, a new homologue of the CD44 glycoprotein, is a lymph-specific receptor for hyaluronan, J Cell Biol 144 (4), 789-801, 1999.
69. Petrova, T.V., Makinen, T., Makela, T.P., Saarela, J., Virtanen, I., Ferrell, R.E., Finegold, D.N., Kerjaschki, D., Yla-Herttuala, S., and Alitalo, K., Lymphatic endothelial reprogramming of vascular endothelial cells by the Prox-1 homeobox transcription factor, EMBO J 21 (17), 4593-4599, 2002.
70. Oliver, G. and Detmar, M., The rediscovery of the lymphatic system: old and new insights into the development and biological function of the lymphatic vasculature, Genes Dev 16 (7), 773-783, 2002.
71. Wigle, J.T., Harvey, N., Detmar, M., Lagutina, I., Grosveld, G., Gunn, M.D., Jackson, D.G., and Oliver, G., An essential role for Prox1 in the induction of the lymphatic endothelial cell phenotype, EMBO J 21 (7), 1505-1513, 2002.
72. Chang, Y., Cesarman, E., Pessin, M.S., Lee, F., Culpepper, J., Knowles, D.M., and Moore, P.S., Identification of herpesvirus-like DNA sequences in AIDS-associated Kaposi’s sarcoma, Science 266 (5192), 1865-1869, 1994.
73. Schwartz, E.J., Dorfman, R.F., and Kohler, S., Human herpesvirus-8 latent nuclear antigen-1 expression in endemic Kaposi sarcoma: an immunohistochemical study of 16 cases, Am J Surg Pathol 27 (12), 1546-1550, 2003.
74. Beyari, M.M., Hodgson, T.A., Cook, R.D., Kondowe, W., Molyneux, E.M., Scully, C.M., Teo, C.G., and Porter, S.R., Multiple human herpesvirus-8 infection, J InfectDis 188 (5), 678-689, 2003.
75. Engels, E.A., Biggar, R.J., Marshall, V.A., Walters, M.A., Gamache, C.J., Whitby, D., and Goedert, J.J., Detection and quantification of Kaposi’s sarcoma-associated herpesvirus to predict AIDS-associated Kaposi’s sarcoma, AIDS 17 (12), 1847-1851, 2003.
76. Newton, R., Ziegler, J., Bourboulia, D., Casabonne, D., Beral, V., Mbidde, E., Carpenter, L., Reeves, G., Parkin, D.M., Wabinga, H., Mbulaiteye, S., Jaffe, H., Weiss, R., and Boshoff, C., The sero-epidemiology of Kaposi’s sarcoma-associated herpesvirus (KSHV=HHV-8) in adults with cancer in Uganda, Int J Cancer 103 (2), 226-232, 2003.
77. Verma, S.C. and Robertson, E.S., Molecular biology and pathogenesis of Kaposi sarcomaassociated herpesvirus, FEMS Microbiol Lett 222 (2), 155-163, 2003.
78. Dezube, B.J., Zambela, M., Sage, D.R., Wang, J.F., and Fingeroth, J.D., Characterization of Kaposi sarcoma-associated herpesvirus=human herpesvirus-8 infection of human vascular endothelial cells: early events, Blood 100 (3), 888-896, 2002.
79. Blasig, C., Zietz, C., Haar, B., Neipel, F., Esser, S., Brockmeyer, N.H., Tschachler, E., Colombini, S., Ensoli, B., and Sturzl, M., Monocytes in Kaposi’s sarcoma lesions are productively infected by human herpesvirus 8, J Virol 71 (10), 7963-7968, 1997.
80. Akula, S.M., Naranatt, P.P., Walia, N.S., Wang, F.Z., Fegley, B., and Chandran, B., Kaposi’s sarcoma-associated herpesvirus (human herpesvirus 8) infection of human fibroblast cells occurs through endocytosis, J Virol 77 (14), 7978-7990, 2003.
81. Akula, S.M., Pramod, N.P., Wang, F.Z., and Chandran, B., Human herpesvirus 8 envelopeassociated glycoproteinB interacts with heparan sulfate-like moieties, Virology 284 (2), 235-249, 2001.
82. Audard, V., Lok, C., Trabattoni, M., Wechsler, J., Brousse, N., and Fraitag, S., [Misleading Kaposi’s sarcoma: usefulness of anti HHV-8 immunostaining], Ann Pathol 23 (4), 345-348, 2003.
83. Hong, A., Davies, S., and Lee, C.S., Immunohistochemical detection of the human herpesvirus 8 (HHV8) latent nuclear antigen-1 in Kaposi’s sarcoma, Pathology 35 (5), 448-450, 2003.
84. Pantanowitz, L., Pinkus, G.S., Dezube, B.J., and Tahan, S.R., HHV8 is not restricted to Kaposi’s sarcoma, Mod Pathol 18 (8), 1148, 2005.
85. Hammock, L., Reisenauer, A., Wang, W., Cohen, C., Birdsong, G., and Folpe, A.L., Latencyassociated nuclear antigen expression and human herpesvirus-8 polymerase chain reaction in the evaluation of Kaposi sarcoma and other vascular tumors in HIV-positive patients, Mod Pathol 18 (4), 463-468, 2005.
86. Kazakov, D.V., Schmid, M., Adams, V., Cathomas, G., Muller, B., Burg, G., and Kempf, W., HHV-8 DNA sequences in the peripheral blood and skin lesions of an HIV-negative patient with multiple eruptive dermatofibromas: implications for the detection of HHV-8 as a diagnostic marker for Kaposi’s sarcoma, Dermatology 206 (3), 217-221, 2003.
87. McDonagh, D.P., Liu, J., Gaffey, M.J., Layfield, L.J., Azumi, N., and Traweek, S.T., Detection of Kaposi’s sarcoma-associated herpesvirus-like DNA sequence in angiosarcoma, Am J Pathol 149 (4), 1363-1368, 1996.
88. Oxholm, A., Epidermal expression of interleukin-6 and tumour necrosis factor-alpha in normal and immunoinflammatory skin states in humans, APMIS Suppl 24, 1-32, 1992.
89. Fiorelli, V., Gendelman, R., Sirianni, M.C., Chang, H.K., Colombini, S., Markham, P.D., Monini, P., Sonnabend, J., Pintus, A., Gallo, R.C., and Ensoli, B., gamma-Interferon produced by CD8þ T cells infiltrating Kaposi’s sarcoma induces spindle cells with angiogenic phenotype and synergy with human immunodeficiency virus-1 Tat protein: an immune response to human herpesvirus-8 infection? Blood 91 (3), 956-967, 1998.
90. Dupin, N., Fisher, C., Kellam, P., Ariad, S., Tulliez, M., Franck, N., van Marck, E., Salmon, D., Gorin, I., Escande, J.P., Weiss, R.A., Alitalo, K., and Boshoff, C., Distribution of human herpesvirus-8 latently infected cells in Kaposi’s sarcoma, multicentric Castleman’s disease, and primary effusion lymphoma, Proc Natl Acad Sci USA 96 (8), 4546-4551, 1999.
91. Bedi, G.C., Westra, W.H., Farzadegan, H., Pitha, P.M., and Sidransky, D., Microsatellite instability in primary neoplasms from HIVþpatients, Nat Med 1 (1), 65-68, 1995.
92. Noel, J.C., De Thier, F., Simonart, T., Andre, J., Hermans, P., Van Vooren, J.P., and Heenen, M., p53 Protein overexpression is a common but late event in the pathogenesis of iatrogenic and AIDSrelated Kaposi’s sarcoma, Arch Dermatol Res 289 (11), 660-661, 1997.
93. Scinicariello, F., Dolan, M.J., Nedelcu, I., Tyring, S.K., and Hilliard, J.K., Occurrence of human papillomavirus and p53 gene mutations in Kaposi’s sarcoma, Virology 203 (1), 153-157, 1994.
94. Nicolaides, A., Huang, Y.Q., Li, J.J., Zhang, W.G., and Friedman-Kien, A.E., Gene amplification and multiple mutations of the K-ras oncogene in Kaposi’s sarcoma, Anticancer Res 14 (3A), 921-926, 1994.
95. Ishihara, K. and Hirano, T., IL-6 in autoimmune disease and chronic inflammatory proliferative disease, Cytokine Growth Factor Rev 13 (4-5), 357-368, 2002.
96. Yoshizaki, K., Nishimoto, N., Matsumoto, K., Tagoh, H., Taga, T., Deguchi, Y., Kuritani, T., Hirano, T., Hashimoto, K., Okada, N., et al., Interleukin 6 and expression of its receptor on epidermal keratinocytes, Cytokine 2 (5), 381-387, 1990.
97. Pati, S., Cavrois, M., Guo, H.G., Foulke, J.S., Jr., Kim, J., Feldman, R.A., and Reitz, M., Activation of NF-kappaB by the human herpesvirus 8 chemokine receptor ORF74: evidence for a paracrine model of Kaposi’s sarcoma pathogenesis, J Virol 75 (18), 8660-8673, 2001.
98. Schwarz, M. and Murphy, P.M., Kaposi’s sarcoma-associated herpesvirus G protein-coupled receptor constitutively activates NF-kappa B and induces proinflammatory cytokine and chemokine production via a C-terminal signaling determinant, J Immunol 167 (1), 505-513, 2001.
99. Deng, H., Song, M.J., Chu, J.T., and Sun, R., Transcriptional regulation of the interleukin-6 gene of human herpesvirus 8 (Kaposi’s sarcoma-associated herpesvirus), J Virol 76 (16), 8252-8264, 2002.
100. West, J.T. and Wood, C., The role of Kaposi’s sarcoma-associated herpesvirus=human herpesvirus-8 regulator of transcription activation (RTA) in control of gene expression, Oncogene 22 (33), 5150-5163, 2003.
101. Nicholas, J., Ruvolo, V.R., Burns, W.H., Sandford, G., Wan, X., Ciufo, D., Hendrickson, S.B., Guo, H.G., Hayward, G.S., and Reitz, M.S., Kaposi’s sarcoma-associated human herpesvirus-8 encodes homologues of macrophage inflammatory protein-1 and interleukin-6, Nat Med 3 (3), 287-292, 1997.
102. Neipel, F., Albrecht, J.C., Ensser, A., Huang, Y.Q., Li, J.J., Friedman-Kien, A.E., and Fleckenstein, B., Human herpesvirus 8 encodes a homolog of interleukin-6, J Virol 71 (1), 839-842, 1997.
103. Mullberg, J., Geib, T., Jostock, T., Hoischen, S.H., Vollmer, P., Voltz, N., Heinz, D., Galle, P.R., Klouche, M., and Rose-John, S., IL-6 receptor independent stimulation of human gp130 by viral IL-6, J Immunol 164 (9), 4672-4677, 2000.
104. Muller-Newen, G., The cytokine receptor gp130: faithfully promiscuous, Sci STKE 2003 (201), PE40, 2003.
105. Stahl, N., Boulton, T.G., Farruggella, T., Ip, N.Y., Davis, S., Witthuhn, B.A., Quelle, F.W., Silvennoinen, O., Barbieri, G., Pellegrini, S., et al., Association and activation of Jak-Tyk kinases by CNTF-LIF-OSM-IL-6 beta receptor components, Science 263 (5143), 92-95, 1994.
106. Lutticken, C., Wegenka, U.M., Yuan, J., Buschmann, J., Schindler, C., Ziemiecki, A., Harpur, A.G., Wilks, A.F., Yasukawa, K., Taga, T., et al., Association of transcription factor APRF and protein kinase Jak1 with the interleukin-6 signal transducer gp130, Science 263 (5143), 89-92, 1994.
107. Bromberg, J. and Darnell, J.E., Jr., The role of STATs in transcriptional control and their impact on cellular function, Oncogene 19 (21), 2468-2473, 2000.
108. Fukada, T., Ohtani, T., Yoshida, Y., Shirogane, T., Nishida, K., Nakajima, K., Hibi, M., and Hirano, T., STAT3 orchestrates contradictory signals in cytokine-induced G1 to S cell-cycle transition, EMBO J 17 (22), 6670-6677, 1998.
109. Tee, A.R., Fingar, D.C., Manning, B.D., Kwiatkowski, D.J., Cantley, L.C., and Blenis, J., Tuberous sclerosis complex-1 and -2 gene products function together to inhibit mammalian target of rapamycin (mTOR)-mediated downstream signaling, Proc Natl Acad Sci USA 99 (21), 13571-13576, 2002.
110. Yao, R. and Cooper, G.M., Requirement for phosphatidylinositol-3 kinase in the prevention of apoptosis by nerve growth factor, Science 267 (5206), 2003-2006, 1995.
111. Manning, B.D., Tee, A.R., Logsdon, M.N., Blenis, J., and Cantley, L.C., Identification of the tuberous sclerosis complex-2 tumor suppressor gene product tuberin as a target of the phosphoinositide 3-kinase=akt pathway, Mol Cell 10 (1), 151-162, 2002.
112. Fukada, T., Hibi, M., Yamanaka, Y., Takahashi-Tezuka, M., Fujitani, Y., Yamaguchi, T., Nakajima, K., and Hirano, T., Two signals are necessary for cell proliferation induced by a cytokine receptor gp130: involvement of STAT3 in anti-apoptosis, Immunity 5 (5), 449-460, 1996.
113. Oh, H., Fujio, Y., Kunisada, K., Hirota, H., Matsui, H., Kishimoto, T., and Yamauchi-Takihara, K., Activation of phosphatidylinositol 3-kinase through glycoprotein 130 induces protein kinase B and p70 S6 kinase phosphorylation in cardiac myocytes, J Biol Chem 273 (16), 9703-9710, 1998.
114. Brugarolas, J.B., Vazquez, F., Reddy, A., Sellers, W.R., and Kaelin, W.G., Jr., TSC2 regulates VEGF through mTOR-dependent and -independent pathways, Cancer Cell 4 (2), 147-158, 2003.
115. Brugarolas, J., Lei, K., Hurley, R.L., Manning, B.D., Reiling, J.H., Hafen, E., Witters, L.A., Ellisen, L.W., and Kaelin, W.G., Jr., Regulation of mTOR function in response to hypoxia by REDD1 and the TSC1=TSC2 tumor suppressor complex, Genes Dev 18 (23), 2893-2904, 2004.
116. Funamoto, M., Fujio, Y., Kunisada, K., Negoro, S., Tone, E., Osugi, T., Hirota, H., Izumi, M., Yoshizaki, K., Walsh, K., Kishimoto, T., and Yamauchi-Takihara, K., Signal transducer and activator of transcription 3 is required for glycoprotein 130-mediated induction of vascular endothelial growth factor in cardiac myocytes, J Biol Chem 275 (14), 10561-10566, 2000.
117. Naruishi, K., Nishimura, F., Yamada-Naruishi, H., Omori, K., Yamaguchi, M., and Takashiba, S., C-jun N-terminal kinase (JNK) inhibitor, SP600125, blocks interleukin (IL)-6-induced vascular endothelial growth factor (VEGF) production: cyclosporine A partially mimics this inhibitory effect, Transplantation 76 (9), 1380-1382, 2003.
118. Liu, C., Okruzhnov, Y., Li, H., and Nicholas, J., Human herpesvirus 8 (HHV-8)-encoded cytokines induce expression of and autocrine signaling by vascular endothelial growth factor (VEGF) in HHV-8-infected primary-effusion lymphoma cell lines and mediate VEGF-independent antiapoptotic effects, J Virol 75 (22), 10933-10940, 2001.
119. Aoki, Y., Jaffe, E.S., Chang, Y., Jones, K., Teruya-Feldstein, J., Moore, P.S., and Tosato, G., Angiogenesis and hematopoiesis induced by Kaposi’s sarcoma-associated herpesvirus-encoded interleukin-6, Blood 93 (12), 4034-4043, 1999.
120. Ensoli, B., Nakamura, S., Salahuddin, S.Z., Biberfeld, P., Larsson, L., Beaver, B., Wong-Staal, F., and Gallo, R.C., AIDS-Kaposi’s sarcoma-derived cells express cytokines with autocrine and paracrine growth effects, Science 243 (4888), 223-226, 1989.
121. Louie, S., Cai, J., Law, R., Lin, G., Lunardi-Iskandar, Y., Jung, B., Masood, R., and Gill, P., Effects of interleukin-1 and interleukin-1 receptor antagonist in AIDS-Kaposi’s sarcoma, J Acquir Immune Defic Syndr Hum Retrovirol 8 (5), 455-460, 1995.
122. Cornali, E., Zietz, C., Benelli, R., Weninger, W., Masiello, L., Breier, G., Tschachler, E., Albini, A., and Sturzl, M., Vascular endothelial growth factor regulates angiogenesis and vascular permeability in Kaposi’s sarcoma, Am J Pathol 149 (6), 1851-1869, 1996.
123. Homey, B., Muller, A., and Zlotnik, A., Chemokines: agents for the immunotherapy of cancer? Nat Rev Immunol 2 (3), 175-184, 2002.
124. Moore, P.S., Boshoff, C., Weiss, R.A., and Chang, Y., Molecular mimicry of human cytokine and cytokine response pathway genes by KSHV, Science 274 (5293), 1739-1744, 1996.
125. Stine, J.T., Wood, C., Hill, M., Epp, A., Raport, C.J., Schweickart, V.L., Endo, Y., Sasaki, T., Simmons, G., Boshoff, C., Clapham, P., Chang, Y., Moore, P., Gray, P.W., and Chantry, D., KSHV-encoded CC chemokine vMIP-III is a CCR4 agonist, stimulates angiogenesis, and selectively chemoattracts TH2 cells, Blood 95 (4), 1151-1157, 2000.
126. Sun, R., Lin, S.F., Staskus, K., Gradoville, L., Grogan, E., Haase, A., and Miller, G., Kinetics of Kaposi’s sarcoma-associated herpesvirus gene expression, J Virol 73 (3), 2232-2242, 1999.
127. Sodhi, A., Montaner, S., and Gutkind, J.S., Viral hijacking of G-protein-coupled-receptor signalling networks, Nat Rev Mol Cell Biol 5 (12), 998-1012, 2004.
128. Dairaghi, D.J., Fan, R.A., McMaster, B.E., Hanley, M.R., and Schall, T.J., HHV8-encoded vMIP-I selectively engages chemokine receptor CCR8. Agonist and antagonist profiles of viral chemokines, J Biol Chem 274 (31), 21569-21574, 1999.
129. Kledal, T.N., Rosenkilde, M.M., Coulin, F., Simmons, G., Johnsen, A.H., Alouani, S., Power, C.A., Luttichau, H.R., Gerstoft, J., Clapham, P.R., Clark-Lewis, I., Wells, T.N., and Schwartz, T.W., A broad-spectrum chemokine antagonist encoded by Kaposi’s sarcoma-associated herpesvirus, Science 277 (5332), 1656-1659, 1997.
130. Boshoff, C., Endo, Y., Collins, P.D., Takeuchi, Y., Reeves, J.D., Schweickart, V.L., Siani, M.A., Sasaki, T., Williams, T.J., Gray, P.W., Moore, P.S., Chang, Y., and Weiss, R.A., Angiogenic and HIV-inhibitory functions of KSHV-encoded chemokines, Science 278 (5336), 290-294, 1997.
131. Bais, C., Santomasso, B., Coso, O., Arvanitakis, L., Raaka, E.G., Gutkind, J.S., Asch, A.S., Cesarman, E., Gershengorn, M.C., and Mesri, E.A., G-protein-coupled receptor of Kaposi’s sarcoma-associated herpesvirus is a viral oncogene and angiogenesis activator, Nature 391 (6662), 86-89, 1998.
132. Arvanitakis, L., Geras-Raaka, E., Varma, A., Gershengorn, M.C., and Cesarman, E., Human herpesvirus KSHV encodes a constitutively active G-protein-coupled receptor linked to cell proliferation, Nature 385 (6614), 347-350, 1997.
133. Rosenkilde, M.M., Kledal, T.N., Holst, P.J., and Schwartz, T.W., Selective elimination of high constitutive activity or chemokine binding in the human herpesvirus 8 encoded seven transmembrane oncogene ORF74, J Biol Chem 275 (34), 26309-26315, 2000.
134. Gershengorn, M.C., Geras-Raaka, E., Varma, A., and Clark-Lewis, I., Chemokines activate Kaposi’s sarcoma-associated herpesvirus G protein-coupled receptor in mammalian cells in culture, J Clin Invest 102 (8), 1469-1472, 1998.
135. Rosenkilde, M.M., Kledal, T.N., Brauner-Osborne, H., and Schwartz, T.W., Agonists and inverse agonists for the herpesvirus 8-encoded constitutively active seven-transmembrane oncogene product, ORF-74, J Biol Chem 274 (2), 956-961, 1999.
136. Montaner, S., Sodhi, A., Molinolo, A., Bugge, T.H., Sawai, E.T., He, Y., Li, Y., Ray, P.E., and Gutkind, J.S., Endothelial infection with KSHV genes in vivo reveals that vGPCR initiates Kaposi’s sarcomagenesis and can promote the tumorigenic potential of viral latent genes, Cancer Cell 3 (1), 23-36, 2003.
137. Montaner, S., Sodhi, A., Pece, S., Mesri, E.A., and Gutkind, J.S., The Kaposi’s sarcoma-associated herpesvirus G protein-coupled receptor promotes endothelial cell survival through the activation of Akt=protein kinase B, Cancer Res 61 (6), 2641-2648, 2001.
138. Sodhi, A., Montaner, S., Patel, V., Zohar, M., Bais, C., Mesri, E.A., and Gutkind, J.S., The Kaposi’s sarcoma-associated herpesvirus G protein-coupled receptor up-regulates vascular endothelial growth factor expression and secretion through mitogen-activated protein kinase and p38 pathways acting on hypoxia-inducible factor 1alpha, Cancer Res 60 (17), 4873-4880, 2000.
139. Hoffman, E.C., Reyes, H., Chu, F.F., Sander, F., Conley, L.H., Brooks, B.A., and Hankinson, O., Cloning of a factor required for activity of the Ah(dioxin) receptor, Science 252 (5008), 954-958, 1991.
140. Wang, G.L. and Semenza, G.L., General involvement of hypoxia-inducible factor 1 in transcriptional response to hypoxia, Proc Natl Acad Sci USA 90 (9), 4304-4308, 1993.
141. Huang, L.E., Gu, J., Schau, M., and Bunn, H.F., Regulation of hypoxia-inducible factor 1alpha is mediated by an O2-dependent degradation domain via the ubiquitin-proteasome pathway, Proc Natl Acad Sci USA 95 (14), 7987-7992, 1998.
142. Bruick, R.K. and McKnight, S.L., A conserved family of prolyl-4-hydroxylases that modify HIF, Science 294 (5545), 1337-1340, 2001.
143. Ivan, M., Kondo, K., Yang, H., Kim, W., Valiando, J., Ohh, M., Salic, A., Asara, J.M., Lane, W.S., and Kaelin, W.G., Jr., HIFalpha targeted for VHL-mediated destruction by proline hydroxylation:implications for O2 sensing, Science 292 (5516), 464-468, 2001.
144. Jaakkola, P., Mole, D.R., Tian, Y.M., Wilson, M.I., Gielbert, J., Gaskell, S.J., Kriegsheim, A., Hebestreit, H.F., Mukherji, M., Schofield, C.J., Maxwell, P.H., Pugh, C.W., and Ratcliffe, P.J., Targeting of HIF-alpha to the von Hippel-Lindau ubiquitylation complex by O2-regulated prolyl hydroxylation, Science 292 (5516), 468-472, 2001.
145. Maxwell, P.H., Wiesener, M.S., Chang, G.W., Clifford, S.C., Vaux, E.C., Cockman, M.E., Wykoff, C.C., Pugh, C.W., Maher, E.R., and Ratcliffe, P.J., The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis, Nature 399 (6733), 271-275, 1999.
146. Ohh, M., Park, C.W., Ivan, M., Hoffman, M.A., Kim, T.Y., Huang, L.E., Pavletich, N., Chau, V., and Kaelin, W.G., Ubiquitination of hypoxia-inducible factor requires direct binding to the betadomain of the von Hippel-Lindau protein, Nat Cell Biol 2 (7), 423-427, 2000.
147. Cockman, M.E., Masson, N., Mole, D.R., Jaakkola, P., Chang, G.W., Clifford, S.C., Maher, E.R., Pugh, C.W., Ratcliffe, P.J., and Maxwell, P.H., Hypoxia inducible factor-alpha binding and ubiquitylation by the von Hippel-Lindau tumor suppressor protein, J Biol Chem 275 (33), 25733-25741, 2000.
148. Tanimoto, K., Makino, Y., Pereira, T., and Poellinger, L., Mechanism of regulation of the hypoxia-inducible factor-1 alpha by the von Hippel-Lindau tumor suppressor protein, EMBO J 19 (16), 4298-4309, 2000.
149. Kamura, T., Sato, S., Iwai, K., Czyzyk-Krzeska, M., Conaway, R.C., and Conaway, J.W., Activation of HIF1alpha ubiquitination by a reconstituted von Hippel-Lindau (VHL) tumor suppressor complex, Proc Natl Acad Sci USA 97 (19), 10430-10435, 2000.
150. Minet, E., Arnould, T., Michel, G., Roland, I., Mottet, D., Raes, M., Remacle, J., and Michiels, C., ERK activation upon hypoxia: involvement in HIF-1 activation, FEBS Lett 468 (1), 53-58, 2000.
151. Acker, T. and Plate, K.H., A role for hypoxia and hypoxia-inducible transcription factors in tumor physiology, J Mol Med 80 (9), 562-575, 2002.
152. Cannon, M., Philpott, N.J., and Cesarman, E., The Kaposi’s sarcoma-associated herpesvirus G protein-coupled receptor has broad signaling effects in primary effusion lymphoma cells, J Virol 77 (1), 57-67, 2003.
153. Montaner, S., Sodhi, A., Servitja, J.M., Ramsdell, A.K., Barac, A., Sawai, E.T., and Gutkind, J.S., The small GTPase Rac1 links the Kaposi sarcoma-associated herpesvirus vGPCR to cytokine secretion and paracrine neoplasia, Blood 104 (9), 2903-2911, 2004.
154. Bais, C., Van Geelen, A., Eroles, P., Mutlu, A., Chiozzini, C., Dias, S., Silverstein, R.L., Rafii, S., and Mesri, E.A., Kaposi’s sarcoma associated herpesvirus G protein-coupled receptor immortalizes human endothelial cells by activation of the VEGF receptor-2= KDR, Cancer Cell 3 (2), 131-143, 2003.
155. Ferrara, N., Gerber, H.P., and LeCouter, J., The biology of VEGF and its receptors, Nat Med 9 (6), 669-676, 2003.
156. Masood, R., Cesarman, E., Smith, D.L., Gill, P.S., and Flore, O., Human herpesvirus-8-transformed endothelial cells have functionally activated vascular endothelial growth factor=vascular endothelial growth factor receptor, Am J Pathol 160 (1), 23-29, 2002.
157. Eswarakumar, V.P., Lax, I., and Schlessinger, J., Cellular signaling by fibroblast growth factor receptors, Cytokine Growth Factor Rev 16 (2), 139-149, 2005.
158. Neufeld, G., Gospodarowicz, D., Dodge, L., and Fujii, D.K., Heparin modulation of the neurotropic effects of acidic and basic fibroblast growth factors and nerve growth factor on PC12 cells, J Cell Physiol 131 (1), 131-140, 1987.
159. Creuzet, C., Loeb, J., and Barbin, G., Fibroblast growth factors stimulate protein tyrosine phosphorylation and mitogen-activated protein kinase activity in primary cultures of hippocampal neurons, J Neurochem 64 (4), 1541-1547, 1995.
160. Kanda, S., Hodgkin, M.N., Woodfield, R.J., Wakelam, M.J., Thomas, G., and Claesson-Welsh, L., Phosphatidylinositol 30-kinase-independent p70 S6 kinase activation by fibroblast growth factor receptor-1 is important for proliferation but not differentiation of endothelial cells, J Biol Chem 272 (37), 23347-23353, 1997.
161. Sinkovics, J.G., Kaposi’s sarcoma: its ‘oncogenes’ and growth factors, Crit Rev Oncol Hematol 11 (2), 87-107, 1991.
162. Samaniego, F., Markham, P.D., Gendelman, R., Watanabe, Y., Kao, V., Kowalski, K., Sonnabend, J.A., Pintus, A., Gallo, R.C., and Ensoli, B., Vascular endothelial growth factor and basic fibroblast growth factor present in Kaposi’s sarcoma (KS) are induced by inflammatory cytokines and synergize to promote vascular permeability and KS lesion development, Am J Pathol 152 (6), 1433-1443, 1998.
163. Barillari, G., Sgadari, C., Palladino, C., Gendelman, R., Caputo, A., Morris, C.B., Nair, B.C., Markham, P., Nel, A., Sturzl, M., and Ensoli, B., Inflammatory cytokines synergize with the HIV-1 Tat protein to promote angiogenesis and Kaposi’s sarcoma via induction of basic fibroblast growth factor and the alpha v beta 3 integrin, J Immunol 163 (4), 1929-1935, 1999.
164. Opalenik, S.R., Shin, J.T., Wehby, J.N., Mahesh, V.K., and Thompson, J.A., The HIV-1 TAT protein induces the expression and extracellular appearance of acidic fibroblast growth factor, J Biol Chem 270 (29), 17457-17467, 1995.
165. Betsholtz, C., Karlsson, L., and Lindahl, P., Developmental roles of platelet-derived growth factors, Bioessays 23 (6), 494-507, 2001.
166. Brennan, P., Babbage, J.W., Burgering, B.M., Groner, B., Reif, K., and Cantrell, D.A., Phosphatidylinositol 3-kinase couples the interleukin-2 receptor to the cell cycle regulator E2F, Immunity 7 (5), 679-689, 1997.
167. Chaudhary, L.R. and Avioli, L.V., Extracellular-signal regulated kinase signaling pathway mediates downregulation of type I procollagen gene expression by FGF-2, PDGF-BB, and okadaic acid in osteoblastic cells, J Cell Biochem 76 (3), 354-359, 2000.
168. Franke, T.F., Yang, S.I., Chan, T.O., Datta, K., Kazlauskas, A., Morrison, D.K., Kaplan, D.R., and Tsichlis, P.N., The protein kinase encoded by the Akt proto-oncogene is a target of the PDGFactivated phosphatidylinositol 3-kinase, Cell 81 (5), 727-736, 1995.
169. Pearson, M.A., O’Farrell, A.M., Dexter, T.M., Whetton, A.D., Owen-Lynch, P.J., and Heyworth, C.M., Investigation of the molecular mechanisms underlying growth factor synergy: the role of ERK 2 activation in synergy, Growth Factors 15 (4), 293-306, 1998.
170. Werner, S., Hofschneider, P.H., Heldin, C.H., Ostman, A., and Roth, W.K., Cultured Kaposi’s sarcoma-derived cells express functional PDGF A-type and B-type receptors, Exp Cell Res 187 (1), 98-103, 1990.
171. Roth, W.K., Werner, S., Schirren, C.G., and Hofschneider, P.H., Depletion of PDGF from serum inhibits growth of AIDS-related and sporadic Kaposi’s sarcoma cells in culture, Oncogene 4 (4), 483-487, 1989.
172. Sturzl, M., Roth, W.K., Brockmeyer, N.H., Zietz, C., Speiser, B., and Hofschneider, P.H., Expression of platelet-derived growth factor and its receptor in AIDS-related Kaposi sarcoma in vivo suggests paracrine and autocrine mechanisms of tumor maintenance, Proc Natl Acad Sci USA 89 (15), 7046-7050, 1992.
173. Lee, H.J., Cho, C.H., Hwang, S.J., Choi, H.H., Kim, K.T., Ahn, S.Y., Kim, J.H., Oh, J.L., Lee, G.M., and Koh, G.Y., Biological characterization of angiopoietin-3 and angiopoietin-4, FASEB J 18 (11), 1200-1208, 2004.
174. Kim, I., Kwak, H.J., Ahn, J.E., So, J.N., Liu, M., Koh, K.N., and Koh, G.Y., Molecular cloning and characterization of a novel angiopoietin family protein, angiopoietin-3, FEBS Lett 443 (3), 353-356, 1999.
175. Maisonpierre, P.C., Suri, C., Jones, P.F., Bartunkova, S., Wiegand, S.J., Radziejewski, C., Compton, D., McClain, J., Aldrich, T.H., Papadopoulos, N., Daly, T.J., Davis, S., Sato, T.N., and Yancopoulos, G.D., Angiopoietin-2, a natural antagonist for Tie2 that disrupts in vivo angiogenesis, Science 277 (5322), 55-60, 1997.
176. Davis, S., Aldrich, T.H., Jones, P.F., Acheson, A., Compton, D.L., Jain, V., Ryan, T.E., Bruno, J., Radziejewski, C., Maisonpierre, P.C., and Yancopoulos, G.D., Isolation of angiopoietin-1, a ligand for the TIE2 receptor, by secretion-trap expression cloning, Cell 87 (7), 1161-1169, 1996.
177. Suri, C., Jones, P.F., Patan, S., Bartunkova, S., Maisonpierre, P.C., Davis, S., Sato, T.N., and Yancopoulos, G.D., Requisite role of angiopoietin-1, a ligand for the TIE2 receptor, during embryonic angiogenesis, Cell 87 (7), 1171-1180, 1996.
178. Oh, H., Takagi, H., Suzuma, K., Otani, A., Matsumura, M., and Honda, Y., Hypoxia and vascular endothelial growth factor selectively up-regulate angiopoietin-2 in bovine microvascular endothelial cells, J Biol Chem 274 (22), 15732-15739, 1999.
179. Lobov, I.B., Brooks, P.C., and Lang, R.A., Angiopoietin-2 displays VEGF-dependent modulation of capillary structure and endothelial cell survival in vivo, Proc Natl Acad Sci USA 99 (17), 11205-11210, 2002.
180. Brown, L.F., Dezube, B.J., Tognazzi, K., Dvorak, H.F., and Yancopoulos, G.D., Expression of Tie1, Tie2, and angiopoietins 1, 2, and 4 in Kaposi’s sarcoma and cutaneous angiosarcoma, Am J Pathol 156 (6), 2179-2183, 2000.
181. Pantanowitz, L. and Dezube, B.J., Advances in the pathobiology and treatment of Kaposi sarcoma, Curr Opin Oncol 16 (5), 443-449, 2004.
182. Alvarez, O.A., Carmichael, D.F., and DeClerck, Y.A., Inhibition of collagenolytic activity and metastasis of tumor cells by a recombinant human tissue inhibitor of metalloproteinases, J Natl Cancer Inst 82 (7), 589-595, 1990.
183. Johnson, M.D., Kim, H.R., Chesler, L., Tsao-Wu, G., Bouck, N., and Polverini, P.J., Inhibition of angiogenesis by tissue inhibitor of metalloproteinase, J Cell Physiol 160 (1), 194-202, 1994.
184. Kruger, A., Fata, J.E., and Khokha, R., Altered tumor growth and metastasis of a T-cell lymphoma in Timp-1 transgenic mice, Blood 90 (5), 1993-2000, 1997.
185. Benelli, R., Adatia, R., Ensoli, B., Stetler-Stevenson, W.G., Santi, L., and Albini, A., Inhibition of AIDS-Kaposi’s sarcoma cell induced endothelial cell invasion by TIMP-2 and a synthetic peptide from the metalloproteinase propeptide: implications for an anti-angiogenic therapy, Oncol Res 6 (6), 251-257, 1994.
186. Bernhard, E.J., Gruber, S.B., and Muschel, R.J., Direct evidence linking expression of matrix metalloproteinase 9 (92-kDa gelatinase=collagenase) to the metastatic phenotype in transformed rat embryo cells, Proc Natl Acad Sci USA 91 (10), 4293-4297, 1994.
187. Kawamata, H., Kameyama, S., Kawai, K., Tanaka, Y., Nan, L., Barch, D.H., Stetler-Stevenson, W.G., and Oyasu, R., Marked acceleration of the metastatic phenotype of a rat bladder carcinoma cell line by the expression of human gelatinase A, Int J Cancer 63 (4), 568-575, 1995.
188. Meade-Tollin, L.C., Way, D., and Witte, M.H., Expression of multiple matrix metalloproteinases and urokinase type plasminogen activator in cultured Kaposi sarcoma cells, Acta Histochem 101 (3), 305-316, 1999.
189. Ray, J.M. and Stetler-Stevenson, W.G., Gelatinase A activity directly modulates melanoma cell adhesion and spreading, EMBO J 14 (5), 908-917, 1995.
190. Toschi, E., Barillari, G., Sgadari, C., Bacigalupo, I., Cereseto, A., Carlei, D., Palladino, C., Zietz, C., Leone, P., Sturzl, M., Butto, S., Cafaro, A., Monini, P., and Ensoli, B., Activation of matrix-metalloproteinase-2 and membrane-type-1-matrix-metalloproteinase in endothelial cells and induction of vascular permeability in vivo by human immunodeficiency virus-1 Tat protein and basic fibroblast growth factor, Mol Biol Cell 12 (10), 2934-2946, 2001.
191. Impola, U., Cuccuru, M.A., Masala, M.V., Jeskanen, L., Cottoni, F., and Saarialho-Kere, U., Preliminary communication: matrix metalloproteinases in Kaposi’s sarcoma, Br J Dermatol 149 (4), 905-907, 2003.
192. Pati, S., Pelser, C.B., Dufraine, J., Bryant, J.L., Reitz, M.S., Jr., and Weichold, F.F., Antitumorigenic effects of HIV protease inhibitor ritonavir: inhibition of Kaposi sarcoma, Blood 99 (10), 3771-3779, 2002.
193. Sgadari, C., Barillari, G., Toschi, E., Carlei, D., Bacigalupo, I., Baccarini, S., Palladino, C., Leone, P., Bugarini, R., Malavasi, L., Cafaro, A., Falchi, M., Valdembri, D., Rezza, G., Bussolino, F., Monini, P., and Ensoli, B., HIV protease inhibitors are potent anti-angiogenic molecules and promote regression of Kaposi sarcoma, Nat Med 8 (3), 225-232, 2002.
194. Golub, L.M., Ramamurthy, N.S., McNamara, T.F., Greenwald, R.A., and Rifkin, B.R., Tetracyclines inhibit connective tissue breakdown: new therapeutic implications for an old family of drugs, Crit Rev Oral Biol Med 2 (3), 297-321, 1991.
195. Cianfrocca, M., Cooley, T.P., Lee, J.Y., Rudek, M.A., Scadden, D.T., Ratner, L., Pluda, J.M., Figg, W.D., Krown, S.E., and Dezube, B.J., Matrix metalloproteinase inhibitor COL-3 in the treatment of AIDS-related Kaposi’s sarcoma: a phase I AIDS malignancy consortium study, J Clin Oncol 20 (1), 153-159, 2002.
196. Dezube, B.J., Krown, S.E., Lee, J.Y., Bauer, K.S., and Aboulafia, D.M., Randomized phase II trial of matrix metalloproteinase inhibitor COL-3 in AIDS-related Kaposi’s sarcoma: an AIDS Malignancy Consortium Study, J Clin Oncol 24 (9), 1389-1394, 2006.
197. Elkin, M., Miao, H.Q., Nagler, A., Aingorn, E., Reich, R., Hemo, I., Dou, H.L., Pines, M., and Vlodavsky, I., Halofuginone: a potent inhibitor of critical steps in angiogenesis progression, FASEB J 14 (15), 2477-2485, 2000.
198. Koon, H.B., Bubley, G.J., Pantanowitz, L., Masiello, D., Smith, B., Crosby, K., Proper, J., Weeden, W., Miller, T.E., Chatis, P., Egorin, M.J., Tahan, S.R., and Dezube, B.J., Imatinibinduced regression of AIDS-related Kaposi’s sarcoma, J Clin Oncol 23 (5), 982-989, 2005.
199. Chaudhary, L.R. and Hruska, K.A., The cell survival signal Akt is differentially activated by PDGF-BB, EGF, and FGF-2 in osteoblastic cells, J Cell Biochem 81 (2), 304-311, 2001.
200. Krown, S.E., Li, P., Von Roenn, J.H., Paredes, J., Huang, J., and Testa, M.A., Efficacy of lowdose interferon with antiretroviral therapy in Kaposi’s sarcoma: a randomized phase II AIDS clinical trials group study, J Interferon Cytokine Res 22 (3), 295-303, 2002.
201. Little, R.F., Wyvill, K.M., Pluda, J.M., Welles, L., Marshall, V., Figg, W.D., Newcomb, F.M., Tosato, G., Feigal, E., Steinberg, S.M., Whitby, D., Goedert, J.J., and Yarchoan, R., Activity of thalidomide in AIDS-related Kaposi’s sarcoma, J Clin Oncol 18 (13), 2593-2602, 2000.
202. Stallone, G., Schena, A., Infante, B., Di Paolo, S., Loverre, A., Maggio, G., Ranieri, E., Gesualdo, L., Schena, F.P., and Grandaliano, G., Sirolimus for Kaposi’s sarcoma in renal-transplant recipients, N Engl J Med 352 (13), 1317-1323, 2005.